Also, a recent systematic review indicates that tirzepatide treatment in adults is associated with reductions in fat mass, relative preservation of lean mass, and decreases in MFI [69], all of which are critical for sarcopenia risk and functional capacity
Hector Perez, MD, lead bariatric surgeon at Renew Bariatrics and an advisor at Bariatric Reports, told Healthline that when it comes to weight loss, its too early to call survodutide a game-changer. [W]hile the reported weight loss number is impressive, we already have very strong performers in this category, he said
Beyond glycaemic control, GLP-1 medications have a significant effect on appetite regulation
While MT-1 doses are often in the 500mcg-1mg range, MT-2 research protocols typically use doses in the 100mcg-500mcg range
56 8.4kg , FDA